Key Highlights:

  • ProBiotix Health is quoted on the Aquis Stock Exchange under LSE:PBX, not on the London Stock Exchange as LSE:PBX.
  • The last recorded trade was 10.85p on 25 August 2026, representing an increase of approximately 16.02% from the previous session’s last trade near 9.35p.
  • On 26 August, Aquis displayed a 10.5p midpoint, with a 9p bid and 12p offer, and no new trade recorded at the time of the snapshot.
  • The official Aquis Market Capitalisation was approximately £16.61m, based on 158.2 million tradable shares—not £12.04m.
  • First-half Revenue increased by 53% to £2.06m, while the company moved from a pre-tax loss to a £79,000 profit.

ProBiotix Health Plc (LSE:PBX) remained on investors’ radar after a single trade lifted the shares by approximately 16.02% during the previous session.

The last recorded transaction on 25 August 2026 involved 27,628 shares at approximately 10.85p. This compared with trades near 9.35p during the preceding session. On 26 August, the official Aquis Quotation showed a midpoint of 10.5p, with the shares available at 9p bid and 12p offer.

No new trade had been recorded on 26 August at the time of the market snapshot, meaning the reported 16.02% rise should be attributed to 25 August rather than presented as a new gain occurring on 26 August.

The distinction is particularly important for ProBiotix because the stock is extremely illiquid. The entire value of the trade that produced the headline movement was only around £3,000. This means the percentage gain reveals more about the limited depth of the order book than the arrival of significant institutional demand.

Nevertheless, the price movement follows genuinely improved interim results, including rapid revenue growth, a wider gross Margin and a swing to profit.

Exchange and Valuation Correction

ProBiotix Health is not listed on the London Stock Exchange. It trades on the Apex segment of the Aquis Stock Exchange under the ticker LSE:PBX.

The company had approximately 158.17 million shares in issue at the end of the first half. At the official Aquis midpoint of 10.5p, its market capitalisation was approximately £16.61m.

The £12.04m valuation in the original draft appears to have been based on an outdated or incomplete share count. Investors should use the official Aquis figure when comparing the company’s valuation with its financial performance.

The 9p bid and 12p offer also represent a spread of approximately 28.6% relative to the midpoint. That exceptionally wide range means investors may be unable to buy or sell meaningful positions close to the displayed 10.5p price.

What Happened to ProBiotix Shares?

The last trade on 25 August was executed at approximately 10.85p, up from the prior session’s last transaction near 9.35p. That produced the reported 16.02% increase.

Only one trade was recorded during the session, involving 27,628 shares with a value of approximately £2,997. No regulatory announcement accompanied the move.

The most plausible explanation is a combination of thin Liquidity and a delayed market response to the company’s interim results, which were released on 6 August.

While the underlying results were positive, one transaction is not sufficient evidence of a broad market revaluation. A subsequent trade could occur closer to either side of the wide bid-offer spread and produce another substantial percentage movement.

Latest Company Developments

ProBiotix has continued expanding its international commercial network through business-to-business partnerships.

The company announced agreements covering Spain and Portugal, Slovakia and Belgium during 2026. The Belgian Partnership involved supplying its probiotic technology to Nutrisan for a new range aimed at pharmacists and healthcare professionals.

Management reported five new partnerships during the first half. The active customer base increased by more than 15%, reflecting broader adoption of the company’s cardiometabolic-health products.

The partnership with ingredients group Kemin also supported strong growth in China. ProBiotix expects additional progress from the Asia-Pacific and EMEA regions during the second half.

The company is repositioning its US strategy for 2027, including third-party distribution and broader Marketing of LP-LDL beyond cholesterol support.

ProBiotix has also begun recruitment for a clinical study examining the possible effect of LP-LDL in prediabetes and diabetes. Positive findings could broaden the commercial proposition, although the clinical work remains exploratory and should not be treated as proof of efficacy in those conditions.

Financial Performance

ProBiotix delivered a clear improvement during the six months ended 30 June 2026.

Revenue increased by 53% to £2.059m from £1.344m in the comparable period. Gross Profit advanced by 66% to £1.245m, while the gross margin widened to 60.4% from approximately 55.7%.

Adjusted EBITDA, excluding share-based payments, moved to a profit of £151,000 from a loss of £112,000. The company reported an operating and pre-tax profit of £79,000, compared with a £153,000 loss one year earlier.

After recognising a small tax credit, total profit for the period reached £86,000. This represented basic Earnings of 0.05p per share.

The cash balance stood at £1.244m, compared with £1.266m at the end of December 2025 and £1.299m in June 2025. The relatively modest reduction indicates that the improved accounting performance was achieved without substantial cash depletion.

Operating cash outflow declined to only £19,000 from £347,000 in the comparable period. Increased receivables absorbed part of the cash generated by the business, highlighting the importance of collecting payments as sales expand.

Management stated that the existing cash balance was sufficient to fund its expansion ambitions. That reduces near-term financing concerns, although sustainable self-funding will depend on continued profitable growth.

The LP-LDL Growth Opportunity

ProBiotix’s principal asset is LP-LDL, its proprietary strain of Lactobacillus plantarum. The strain has been developed to support cardiometabolic health and is protected through patents, pending applications and trademarks.

The company operates primarily through a business-to-business model. Rather than spending heavily to build a global consumer brand, ProBiotix supplies ingredients, private-label products and finished formulations to established partners.

This approach can support attractive margins because partners provide local distribution, marketing and customer relationships. It also allows ProBiotix to enter multiple countries without establishing expensive standalone sales organisations.

Demand is supported by consumer interest in healthy ageing, cholesterol management, preventive health and scientifically supported nutritional products.

If existing partners generate repeat orders and newly signed agreements progress to commercial sales, the model could provide operating leverage. The widened first-half gross margin and move into EBITDA profitability offer early evidence of that potential.

However, the Business remains small. Even strong percentage growth translates into modest absolute revenue, and quarterly performance may be affected by the timing of individual customer orders.

Customer Concentration Risk

The most significant company-specific risk is customer concentration.

One customer generated £1.014m of first-half revenue, equivalent to 49.2% of the group total. In the comparable period, the largest customer represented 51.2% of revenue.

The proportion has declined slightly, but ProBiotix remains highly dependent on a single commercial relationship. A reduction in orders, contract renegotiation, payment delay or loss of that customer could materially affect revenue and profitability.

Growth in the wider customer base is therefore important not only for expansion but also for reducing risk. The five new partnerships announced during the period will need to convert into meaningful recurring sales before the revenue mix becomes materially more diversified.

Other Risks Investors Should Watch

The company has only recently moved into profit, and the absolute earnings remain modest. A slowdown in sales, increased Investment or higher operating costs could return the business to a loss.

Trade receivables increased to £560,000 from £351,000 at the end of 2025. This is consistent with rising sales, but investors should monitor cash collection and working-capital requirements.

The probiotics and nutritional-supplement market is highly competitive. ProBiotix must continue demonstrating scientific differentiation while protecting its intellectual property and regulatory claims.

Foreign-currency movements may affect reported results because most first-half revenue was generated outside the UK. The US accounted for approximately £1.05m, China contributed £276,000 and other international markets generated £735,000, while no UK revenue was recorded.

Share-price liquidity is another major concern. The wide spread and extremely low trading Volume can make both entry and exit difficult and can produce price movements disconnected from changes in fundamental value.

What Could Drive the Shares Next?

Further distribution, licensing or private-label agreements could strengthen confidence in the commercial strategy.

Investors will also watch for evidence that the five new partnerships are generating repeat revenue rather than isolated initial orders. Continued growth in China through Kemin would reinforce the international expansion narrative.

The full-year results will provide the clearest test of whether first-half profitability can be sustained. Maintaining EBITDA profitability while continuing to grow cash resources would represent an important milestone.

Progress with the clinical study in prediabetes and diabetes could broaden the long-term opportunity, although investors should wait for properly analysed study results before assigning material value.

On the downside, weaker orders from the largest customer, slower growth in Asia-Pacific or renewed cash burn could reverse recent optimism.

The Bottom Line

ProBiotix Health’s last recorded trade increased by approximately 16.02% to 10.85p on 25 August 2026. On 26 August, Aquis displayed a midpoint of 10.5p with a wide 9p-to-12p spread and no new transaction at the time of the snapshot.

The movement was driven by a single trade worth approximately £3,000 and should therefore not be interpreted as evidence of substantial institutional buying.

The underlying financial direction has nevertheless improved meaningfully. Revenue increased by 53%, the gross margin widened, adjusted EBITDA became positive and the company reported its first-half pre-tax profit while largely preserving its cash balance.

Those gains are offset by heavy dependence on one customer, limited absolute profitability and exceptionally poor share liquidity. ProBiotix has begun demonstrating that its partnership model can produce profitable growth, but a sustained Revaluation will require continued revenue expansion, customer Diversification and repeatable cash generation.